Familial hypercholesterolaemia

A model of care for Australasia

Gerald F. Watts, David R. Sullivan, Nicola Poplawski, Frank van Bockxmeer, Ian Hamilton-Craig, Peter M. Clifton, Richard O'Brien, Warrick Bishop, Peter George, Phillip J. Barter, Timothy Bates, John R. Burnett, John Coakley, Patricia M Davidson, Jon Emery, Andrew Martin, Waleed Farid, Lucinda Freeman, Elizabeth Geelhoed, Amanda Juniper & 14 others Alexa Kidd, Karam Kostner, Ines Krass, Michael Livingston, Suzy Maxwell, Peter O'Leary, Amal Owaimrin, Trevor G. Redgrave, Nicola Reid, Lynda Southwell, Graeme Suthers, Andrew Tonkin, Simon Towler, Ronald Trent

Research output: Contribution to journalArticle

Abstract

Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remains undetected and those diagnosed with the condition are inadequately treated.To bridge this major gap in coronary prevention the FH Australasia Network (Australian Atherosclerosis Society) has developed a consensus model of care (MoC) for FH. The MoC is based on clinical experience, expert opinion, published evidence and consultations with a wide spectrum of stakeholders, and has been developed for use primarily by specialist centres intending starting a clinical service for FH. This MoC aims to provide a standardised, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes.The MoC for FH is presented as a series of recommendations and algorithms focusing on the standards required for the detection, diagnosis, assessment and management of FH in adults and children. The process involved in cascade screening and risk notification, the backbone for detecting new cases of FH, is detailed. Guidance on treatment is based on risk stratifying patients, management of non-cholesterol risk factors, safe and effective use of statins, and a rational approach to follow-up of patients. Clinical and laboratory recommendations are given for genetic testing. An integrative system for providing best clinical care is described.This MoC for FH is not prescriptive and needs to be complemented by good clinical judgment and adjusted for local needs and resources. After initial implementation, the MoC will require critical evaluation, development and appropriate modification.

Original languageEnglish (US)
Pages (from-to)221-263
Number of pages43
JournalAtherosclerosis Supplements
Volume12
Issue number2
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Australasia
Hyperlipoproteinemia Type II
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Expert Testimony
Genetic Testing
New Zealand
Coronary Disease
Atherosclerosis
Consensus
Referral and Consultation
Cholesterol
Parturition

Keywords

  • Adolescents
  • Adults
  • Assessment
  • Cascade screening
  • Children
  • Diagnosis
  • Familial hypercholesterolaemia
  • Genetic testing
  • Model of care
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Watts, G. F., Sullivan, D. R., Poplawski, N., van Bockxmeer, F., Hamilton-Craig, I., Clifton, P. M., ... Trent, R. (2011). Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 12(2), 221-263. https://doi.org/10.1016/j.atherosclerosissup.2011.06.001

Familial hypercholesterolaemia : A model of care for Australasia. / Watts, Gerald F.; Sullivan, David R.; Poplawski, Nicola; van Bockxmeer, Frank; Hamilton-Craig, Ian; Clifton, Peter M.; O'Brien, Richard; Bishop, Warrick; George, Peter; Barter, Phillip J.; Bates, Timothy; Burnett, John R.; Coakley, John; Davidson, Patricia M; Emery, Jon; Martin, Andrew; Farid, Waleed; Freeman, Lucinda; Geelhoed, Elizabeth; Juniper, Amanda; Kidd, Alexa; Kostner, Karam; Krass, Ines; Livingston, Michael; Maxwell, Suzy; O'Leary, Peter; Owaimrin, Amal; Redgrave, Trevor G.; Reid, Nicola; Southwell, Lynda; Suthers, Graeme; Tonkin, Andrew; Towler, Simon; Trent, Ronald.

In: Atherosclerosis Supplements, Vol. 12, No. 2, 10.2011, p. 221-263.

Research output: Contribution to journalArticle

Watts, GF, Sullivan, DR, Poplawski, N, van Bockxmeer, F, Hamilton-Craig, I, Clifton, PM, O'Brien, R, Bishop, W, George, P, Barter, PJ, Bates, T, Burnett, JR, Coakley, J, Davidson, PM, Emery, J, Martin, A, Farid, W, Freeman, L, Geelhoed, E, Juniper, A, Kidd, A, Kostner, K, Krass, I, Livingston, M, Maxwell, S, O'Leary, P, Owaimrin, A, Redgrave, TG, Reid, N, Southwell, L, Suthers, G, Tonkin, A, Towler, S & Trent, R 2011, 'Familial hypercholesterolaemia: A model of care for Australasia', Atherosclerosis Supplements, vol. 12, no. 2, pp. 221-263. https://doi.org/10.1016/j.atherosclerosissup.2011.06.001
Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM et al. Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements. 2011 Oct;12(2):221-263. https://doi.org/10.1016/j.atherosclerosissup.2011.06.001
Watts, Gerald F. ; Sullivan, David R. ; Poplawski, Nicola ; van Bockxmeer, Frank ; Hamilton-Craig, Ian ; Clifton, Peter M. ; O'Brien, Richard ; Bishop, Warrick ; George, Peter ; Barter, Phillip J. ; Bates, Timothy ; Burnett, John R. ; Coakley, John ; Davidson, Patricia M ; Emery, Jon ; Martin, Andrew ; Farid, Waleed ; Freeman, Lucinda ; Geelhoed, Elizabeth ; Juniper, Amanda ; Kidd, Alexa ; Kostner, Karam ; Krass, Ines ; Livingston, Michael ; Maxwell, Suzy ; O'Leary, Peter ; Owaimrin, Amal ; Redgrave, Trevor G. ; Reid, Nicola ; Southwell, Lynda ; Suthers, Graeme ; Tonkin, Andrew ; Towler, Simon ; Trent, Ronald. / Familial hypercholesterolaemia : A model of care for Australasia. In: Atherosclerosis Supplements. 2011 ; Vol. 12, No. 2. pp. 221-263.
@article{006f2ed9685f4ab591cd5bdf750ad4c4,
title = "Familial hypercholesterolaemia: A model of care for Australasia",
abstract = "Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remains undetected and those diagnosed with the condition are inadequately treated.To bridge this major gap in coronary prevention the FH Australasia Network (Australian Atherosclerosis Society) has developed a consensus model of care (MoC) for FH. The MoC is based on clinical experience, expert opinion, published evidence and consultations with a wide spectrum of stakeholders, and has been developed for use primarily by specialist centres intending starting a clinical service for FH. This MoC aims to provide a standardised, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes.The MoC for FH is presented as a series of recommendations and algorithms focusing on the standards required for the detection, diagnosis, assessment and management of FH in adults and children. The process involved in cascade screening and risk notification, the backbone for detecting new cases of FH, is detailed. Guidance on treatment is based on risk stratifying patients, management of non-cholesterol risk factors, safe and effective use of statins, and a rational approach to follow-up of patients. Clinical and laboratory recommendations are given for genetic testing. An integrative system for providing best clinical care is described.This MoC for FH is not prescriptive and needs to be complemented by good clinical judgment and adjusted for local needs and resources. After initial implementation, the MoC will require critical evaluation, development and appropriate modification.",
keywords = "Adolescents, Adults, Assessment, Cascade screening, Children, Diagnosis, Familial hypercholesterolaemia, Genetic testing, Model of care, Treatment",
author = "Watts, {Gerald F.} and Sullivan, {David R.} and Nicola Poplawski and {van Bockxmeer}, Frank and Ian Hamilton-Craig and Clifton, {Peter M.} and Richard O'Brien and Warrick Bishop and Peter George and Barter, {Phillip J.} and Timothy Bates and Burnett, {John R.} and John Coakley and Davidson, {Patricia M} and Jon Emery and Andrew Martin and Waleed Farid and Lucinda Freeman and Elizabeth Geelhoed and Amanda Juniper and Alexa Kidd and Karam Kostner and Ines Krass and Michael Livingston and Suzy Maxwell and Peter O'Leary and Amal Owaimrin and Redgrave, {Trevor G.} and Nicola Reid and Lynda Southwell and Graeme Suthers and Andrew Tonkin and Simon Towler and Ronald Trent",
year = "2011",
month = "10",
doi = "10.1016/j.atherosclerosissup.2011.06.001",
language = "English (US)",
volume = "12",
pages = "221--263",
journal = "Atherosclerosis Supplements",
issn = "1567-5688",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Familial hypercholesterolaemia

T2 - A model of care for Australasia

AU - Watts, Gerald F.

AU - Sullivan, David R.

AU - Poplawski, Nicola

AU - van Bockxmeer, Frank

AU - Hamilton-Craig, Ian

AU - Clifton, Peter M.

AU - O'Brien, Richard

AU - Bishop, Warrick

AU - George, Peter

AU - Barter, Phillip J.

AU - Bates, Timothy

AU - Burnett, John R.

AU - Coakley, John

AU - Davidson, Patricia M

AU - Emery, Jon

AU - Martin, Andrew

AU - Farid, Waleed

AU - Freeman, Lucinda

AU - Geelhoed, Elizabeth

AU - Juniper, Amanda

AU - Kidd, Alexa

AU - Kostner, Karam

AU - Krass, Ines

AU - Livingston, Michael

AU - Maxwell, Suzy

AU - O'Leary, Peter

AU - Owaimrin, Amal

AU - Redgrave, Trevor G.

AU - Reid, Nicola

AU - Southwell, Lynda

AU - Suthers, Graeme

AU - Tonkin, Andrew

AU - Towler, Simon

AU - Trent, Ronald

PY - 2011/10

Y1 - 2011/10

N2 - Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remains undetected and those diagnosed with the condition are inadequately treated.To bridge this major gap in coronary prevention the FH Australasia Network (Australian Atherosclerosis Society) has developed a consensus model of care (MoC) for FH. The MoC is based on clinical experience, expert opinion, published evidence and consultations with a wide spectrum of stakeholders, and has been developed for use primarily by specialist centres intending starting a clinical service for FH. This MoC aims to provide a standardised, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes.The MoC for FH is presented as a series of recommendations and algorithms focusing on the standards required for the detection, diagnosis, assessment and management of FH in adults and children. The process involved in cascade screening and risk notification, the backbone for detecting new cases of FH, is detailed. Guidance on treatment is based on risk stratifying patients, management of non-cholesterol risk factors, safe and effective use of statins, and a rational approach to follow-up of patients. Clinical and laboratory recommendations are given for genetic testing. An integrative system for providing best clinical care is described.This MoC for FH is not prescriptive and needs to be complemented by good clinical judgment and adjusted for local needs and resources. After initial implementation, the MoC will require critical evaluation, development and appropriate modification.

AB - Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remains undetected and those diagnosed with the condition are inadequately treated.To bridge this major gap in coronary prevention the FH Australasia Network (Australian Atherosclerosis Society) has developed a consensus model of care (MoC) for FH. The MoC is based on clinical experience, expert opinion, published evidence and consultations with a wide spectrum of stakeholders, and has been developed for use primarily by specialist centres intending starting a clinical service for FH. This MoC aims to provide a standardised, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes.The MoC for FH is presented as a series of recommendations and algorithms focusing on the standards required for the detection, diagnosis, assessment and management of FH in adults and children. The process involved in cascade screening and risk notification, the backbone for detecting new cases of FH, is detailed. Guidance on treatment is based on risk stratifying patients, management of non-cholesterol risk factors, safe and effective use of statins, and a rational approach to follow-up of patients. Clinical and laboratory recommendations are given for genetic testing. An integrative system for providing best clinical care is described.This MoC for FH is not prescriptive and needs to be complemented by good clinical judgment and adjusted for local needs and resources. After initial implementation, the MoC will require critical evaluation, development and appropriate modification.

KW - Adolescents

KW - Adults

KW - Assessment

KW - Cascade screening

KW - Children

KW - Diagnosis

KW - Familial hypercholesterolaemia

KW - Genetic testing

KW - Model of care

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84855501197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855501197&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosissup.2011.06.001

DO - 10.1016/j.atherosclerosissup.2011.06.001

M3 - Article

VL - 12

SP - 221

EP - 263

JO - Atherosclerosis Supplements

JF - Atherosclerosis Supplements

SN - 1567-5688

IS - 2

ER -